![]() | ![]() |
Formats:
|
||||||||||||||||||||
Copyright © 2005, Cold Spring Harbor Laboratory Press Regulation of an intergenic transcript controls adjacent gene transcription in Saccharomyces cerevisiae 1Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA 2Present address: Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA 3Present address: Laboratory of Yeast Genetics and Cell Biology, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA. 4Correpsonding author. E-MAIL winston/at/genetics.med.harvard.edu; FAX (617) 432-6506. Received August 23, 2005; Accepted September 19, 2005. This article has been cited by other articles in PMC.Abstract Recent studies have revealed that transcription of noncoding, intergenic DNA is abundant among eukaryotes. However, the functions of this transcription are poorly understood. We have previously shown that in Saccharomyces cerevisiae, expression of an intergenic transcript, SRG1, represses the transcription of the adjacent gene, SER3, by transcription interference. We now show that SRG1 transcription is regulated by serine, thereby conferring regulation of SER3, a serine biosynthetic gene. This regulation requires Cha4, a serine-dependent activator that binds to the SRG1 promoter and is required for SRG1 induction in the presence of serine. Furthermore, two coactivator complexes, SAGA and Swi/Snf, are also directly required for activation of SRG1 and transcription interference of SER3. Taken together, our results elucidate a physiological role for intergenic transcription in the regulation of SER3. Moreover, our results demonstrate a mechanism by which intergenic transcription allows activators to act indirectly as repressors. Keywords: Intergenic transcription, noncoding RNA, transcription interference, transcription The analysis of genome-wide transcription in many organisms, including bacteria, yeast, Drosophila, Arabidopsis, mouse, and human, has yielded a common, yet unexpected feature. In addition to the transcription of protein-coding sequences, there is also widespread transcription across non-protein-coding regions (for reviews, see Mattick 2003; Morey and Avner 2004; Huttenhofer et al. 2005; Johnson et al. 2005). In humans, such noncoding transcripts have been detected from intergenic DNA, from introns, and from antisense transcription of exons (Chen et al. 2002; Kapranov et al. 2002; Saha et al. 2002; Bertone et al. 2004; Kampa et al. 2004; Cheng et al. 2005). Additional analysis suggests that much of this transcription is regulated and, thus, may itself play regulatory roles (Cawley et al. 2004; Kim et al. 2005). Recent experiments in the yeast Saccharomyces cerevisiae have also provided evidence for extensive transcription of noncoding regions (Hurowitz and Brown 2003; Havilio et al. 2005; Wyers et al. 2005). One large and broad class of noncoding RNAs that has been studied in prokaryotes and eukaryotes plays direct roles in the regulation of gene expression (for reviews, see Bernstein and Allis 2005; Storz et al. 2005). These regulatory noncoding RNAs have been shown to function at many different levels of gene expression. In Escherichia coli, >50 small noncoding RNA regulators have been identified (for reviews, see Gottesman 2004; Storz et al. 2005). In eukaryotes, one intensively studied group, short interfering RNAs (siRNAs), has been shown to control both chromatin structure and mRNA stability (for reviews, see Meister and Tuschl 2004; Bernstein and Allis 2005). Other well studied eukaryotic categories include the Xist and Tsix RNAs that are involved in X-inactivation in mammals, and the roX1 and roX2 RNAs that are required for dosage compensation in Drosophila (for reviews, see Andersen and Panning 2003; Bernstein and Allis 2005). In addition to these examples, noncoding RNAs have been shown to regulate virtually all known steps of gene expression from transcription initiation to mRNA translation. Several studies have suggested a second class of noncoding transcription that plays an important role in transcription regulation. In this second class, it is the act of transcription that confers activation, rather than the RNA product itself (for review, see Morey and Avner 2004). One example of this type of regulation occurs in the Drosophila bithorax complex (BX-C). Several early studies demonstrated that transcription occurs across noncoding regions at BX-C, suggesting a possible role in mediating repression by the Polycomb group (PcG) complexes (Lipshitz et al. 1987; Sanchez-Herrero and Akam 1989; Cumberledge et al. 1990). More recent studies have shown a correlation between intergenic transcription across PcG response elements (PREs) at the BX-C locus and the relief of silencing by PcG complexes (Bender and Fitzgerald 2002; Hogga and Karch 2002; Rank et al. 2002). Most recently, studies using a transgenic reporter system have demonstrated that transcription in either direction across a PRE blocks repression by PcG complexes and that this activated state is inheritable (Schmitt et al. 2005). A second example occurs at the 50-kb human β-globin locus, where developmentally regulated intergenic transcription occurs in three large chromatin subdomains and is required for the proper developmental regulation of the five globin genes within this locus (Gribnau et al. 2000). The domains of intergenic transcription correlate with the regions of DNase I sensitivity, again strongly suggesting that transcription confers chromatin changes. In contrast to cases in which intergenic transcription activates gene expression, we recently reported a case in S. cerevisiae in which intergenic transcription represses gene expression (Martens et al. 2004). Our work identified a noncoding RNA, SRG1, which is transcribed from intergenic DNA, and showed that transcription of SRG1 across the promoter of the adjacent SER3 gene represses SER3 transcription. We provided evidence for a model in which transcription of SRG1 represses SER3 expression by transcription interference. However, the role of SRG1 in normal SER3 regulation was not addressed. In this work, we use the S. cerevisiae SRG1/SER3 system to provide new insights into the physiological role in regulation by an intergenic transcript. First, we show that SRG1 transcription is induced by high serine levels, resulting in repression of SER3. Second, we identify the serine-responsive activator Cha4 as acting directly in SRG1 induction, thereby indirectly repressing SER3. Third, we show that Cha4 recruits the SAGA and Swi/Snf coactivator complexes to the SRG1 promoter in a serine-dependent manner. Finally, we show that both SAGA and Swi/Snf are required for SER3 repression by facilitating Cha4-dependent activation of SRG1. Taken together, our results show that a physiological response to serine, repression of SER3 transcription, occurs by activating SRG1 intergenic transcription. Based on these results and previous work that implicates Cha4 as a direct activator of the serine catabolism CHA1 gene (Holmberg and Schjerling 1996; Sabet et al. 2003), intergenic transcription provides a mechanism for a single protein to simultaneously activate and repress opposing pathways. Results Serine-dependent regulation of SER3 requires the expression of SRG1 from intergenic DNA We have previously shown that transcription of SER3 is strongly repressed in YPD, a serine-containing medium, by transcription of SRG1 from intergenic DNA (Fig. 1A
Next we tested whether transcription of SRG1 is required for the serine-dependent regulation of SER3. To do this we examined RNA levels in an srg1-1 mutant in which mutation of the SRG1 TATA sequence greatly reduces SRG1 RNA levels. In the srg1-1 mutant, SER3 was expressed at high levels independently of the presence or absence of serine (Fig. 1B Cha4 binds to the SRG1 promoter to control serine-dependent transcription of SRG1 To test for a serine-dependent response element within the SRG1 promoter, we constructed mutations that delete four SRG1 promoter sequences that are highly conserved between S. cerevisiae and closely-related yeasts (labeled 1–4 in Fig. 1A
Further sequence inspection revealed that the UAS3 region overlaps a putative binding site (TGGAGATA CATCTCCA) for Cha4, an S. cerevisiae activator. Cha4 has been previously shown to be a serine-responsive activator of the CHA1 gene, which encodes an enzyme involved in serine catabolism (Holmberg and Schjerling 1996; Sabet et al. 2003). To determine whether Cha4 plays a role in activating SRG1 transcription we constructed and tested three mutations: a deletion of CHA4 (cha4Δ), and both a deletion (srg1-25) and a multiple-point mutant (srg1-26) of the putative Cha4-binding site. By Northern analysis, we observed greatly decreased levels of SRG1 RNA in all three mutants as compared with a wild-type strain when these strains were grown in SD + ser (Fig. 2B To confirm a direct role for Cha4 in serine-dependent activation of SRG1, we assayed Cha4 physical association with both the SRG1 and SER3 promoters by chromatin immunoprecipitation (ChIP). Our results show that when cells are grown in SD + ser, Cha4 strongly associates with the UAS region of the SRG1 promoter (Fig. 3A
To test if Cha4 binding to SRG1 is serine dependent, we compared Cha4 binding in minimal media with or without serine. Cha4 binding was only mildly decreased after shifting cells to SD medium for 25 min (Fig. 3A The Spt3 and Spt8 subunits of SAGA are required to repress SER3 Whole-genome expression analyses originally highlighted SER3 as a gene with interesting regulation, as those studies suggested that both Swi/Snf (Holstege et al. 1998; Sudarsanam et al. 2000) and SAGA (Holstege et al. 1998) serve as repressors of SER3. Our more recent studies have examined the role of Swi/Snf in SER3 repression (Martens and Winston 2002; Martens et al. 2004). Now, to further investigate the role of SAGA in SER3 repression, we measured SER3 mRNA levels in eleven mutants, each lacking a different SAGA subunit and impairing different SAGA actitivies. Our results show that only particular classes of SAGA components are required for SER3 repression. Two SAGA mutants believed to impair TBP recruitment, spt3Δ and spt8Δ, both had dramatically increased levels of SER3 mRNA, similar to that previously observed for a deletion of SNF2, which encodes the catalytic subunit of the Swi/Snf chromatin remodeling complex (Fig. 4A
To address the roles of both SAGA and Swi/Snf in activating SRG1 transcription, we assayed SRG1 RNA levels in both spt3Δ and snf2Δ mutants. To look under conditions maximally inducing for SRG1, cells were grown in SD + ser medium. Northern analysis shows that the serine-induced levels of SRG1 were decreased, albeit modestly, in both mutants compared with wild type. In the snf2Δ mutant, induction of SRG1 was reduced 1.5-fold to twofold (Fig. 4B Association of SAGA and Swi/Snf to the SRG1 promoter is dependent on Cha4 and serine Our results show that Cha4, Spt3, and Snf2 are required for full induction of SRG1 in medium with serine, suggesting that Cha4 recruits SAGA and Swi/Snf to the SRG1 UAS. To test this possibility, we performed ChIP experiments on Swi2 of Swi/Snf (Fig. 5A
Serine-dependent activation by Cha4 appears to involve a step that occurs subsequent to Cha4 binding (Fig. 3B Both SAGA and Swi/Snf are required for SRG1-mediated transcription interference Because snf2Δ and spt3Δ have only modest defects in SRG1 transcription we performed experiments to determine the effects of these mutations on transcription interference by SRG1. Since the direct activators of SER3 have not been identified, we integrated the SRG1 promoter at the GAL1 locus, 5′ of the GAL1 UAS (Fig. 6A
Discussion In this work we have elucidated a physiological role for an intergenic transcript in gene regulation. Our results have shown that the repression of the S. cerevisiae SER3 gene in response to high levels of serine occurs by the induction of intergenic transcription of SRG1. Our results also show that the serine-dependent induction of SRG1 depends upon Cha4, which binds to the SRG1 promoter, and that activation by Cha4 requires the SAGA and Swi/Snf coactivator complexes. Taken together with previous studies (Holmberg and Schjerling 1996; Sabet et al. 2003), our results suggest a model in which the control of SRG1 intergenic transcription is the primary mechanism that regulates SER3 in response to changes in serine. In this model, SRG1 transcription also allows Cha4 to serve as both an activator and repressor of transcription. When cells are exposed to high levels of serine, Cha4 directly activates the CHA1 gene, required for serine catabolism, and indirectly represses the SER3 gene via activation of SRG1 (Fig. 7
In addition to the factors identified in this work that control SRG1 transcription in response to serine levels, other physiological conditions and factors may play important roles in this regulatory system. Sequence conservation suggests that, in addition to the Cha4-binding site, other SRG1 promoter sequences may be required for SRG1 transcription under some conditions (Fig. 2A Another aspect of the SER3/SRG1 regulatory system that remains to be determined is the role of serine in the Cha4-dependent recruitment of SAGA and Swi/Snf. Like many S. cerevisiae activators that respond to intracellular metabolites (for review, see Sellick and Reece 2005), Cha4 binding to DNA is not significantly affected by serine levels (our results; Sabet et al. 2003). Possibly, serine or an intermediate in the serine biosynthetic pathway directly modulates Cha4 activity by inducing a conformational change that facilitates recruitment of SAGA and Swi/Snf. A similar mechanism has been suggested for Put3, an activator of the proline-utilization pathway, as proline directly interacts with Put3 to cause conformational changes that induce the transcription activity of Put3 (Axelrod et al. 1991; Sellick and Reece 2003). Alternatively, serine may indirectly control Cha4 activity by controlling the interaction of Cha4 with an as-yet-unidentified second protein, similar to the galactose-mediated regulation of Gal4 by interaction with Gal80 (Sellick and Reece 2005). A number of different mechanisms have been proposed for transcription interference (for review, see Shearwin et al. 2005) and other naturally occurring cases of transcription interference have been identified (for examples, see Hausler and Somerville 1979; Cullen et al. 1984; Proudfoot 1986; Corbin and Maniatis 1989; Boussadia et al. 1997; Moseley et al. 2002). Our data show that loss of either SAGA or Swi/Snf causes only a two- to threefold decrease in SRG1 RNA levels, yet this modest decrease appears to be sufficient to abolish interference as it is accompanied by a 50-fold increase in SER3 mRNA levels. One possibility is that there is a threshold level of SRG1 transcription that is sufficient to confer transcription interference and that a modest decrease in that level allows activators full access to the SER3 promoter. However, given the modest effects on SRG1 RNA levels observed in the snf2Δ and spt3Δ mutants, SAGA and Swi/Snf may play additional roles to repress SER3 besides SRG1 activation. Consistent with this possibility, Snf2-dependent changes in chromatin structure extend to the SER3 TATA sequence (Martens and Winston 2002). Therefore, there may be two roles for Swi/Snf in SER3 repression, through activation of SRG1 and by inhibition of factor binding to the SER3 promoter. In conclusion, our work has demonstrated a mechanism by which the regulation of noncoding, intergenic transcription provides a physiologically important response in a metabolic signaling pathway. Studies in other systems, including the Drosophila BX-C complex and the human β-globin locus, have demonstrated other cases where regulation of noncoding, intergenic transcription plays important regulatory roles (Gribnau et al. 2000; Schmitt et al. 2005). Additional recent studies have shown that noncoding transcription is widespread (Mattick 2003; Morey and Avner 2004; Huttenhofer et al. 2005; Johnson et al. 2005) and that a significant fraction is regulated (Cawley et al. 2004; Kim et al. 2005). Taken together, these studies suggest that the control of noncoding, intergenic transcription may represent a broadly used mechanism for transcriptional regulation. Materials and methods S. cerevisiae strains and media All S. cerevisiae strains used (Table 1) are isogenic with a GAL2+ derivative of S288C (Winston et al. 1995). Strains were constructed by standard methods, either by crosses or by transformation (Ausubel et al. 1991). Details are available upon request. The spt8Δ302::LEU2 (Eisenmann et al. 1994), spt3-202 (Winston and Minehart 1986), spt3Δ203::TRP1 (Happel and Winston 1992), spt7Δ402::LEU2 (Gansheroff et al. 1995), spt20Δ100::URA3 (Roberts and Winston 1996), snf2Δ::LEU2 (Cairns et al. 1996), snf2Δ1::HIS3 (Abrams et al. 1986), gcn5Δ::HIS3 (Roberts and Winston 1997), ser33Δ0::kanMX (Martens and Winston 2002), srg1-1 (Martens et al. 2004), RPB3-HA::LEU2 (Kolodziej et al. 1990), SNF2-C18myc::TRP1 (Martens and Winston 2002), and cha4Δ0::kanMX (Open Biosystems) alleles have been previously described. The ada2Δ::HIS3, ada1Δ::HIS3, and ada3Δ::HIS3 mutations were constructed by replacing their open reading frames with HIS3 (S. Roberts and F. Winston, unpubl.). The ubp8Δ0::kanMX, sgf29Δ0::kanMX, and sgf73Δ0::kanMX mutations were constructed by replacing their open reading frames with the kanMX marker (Brachmann et al. 1998). The srg1-20 mutation replaces SRG1 promoter sequences from –660 to –560 (relative to the SER3 ATG) with three copies of the myc epitope. The srg1-21, srg1-22, srg1-23, srg1-24, and srg1-25 mutations replace SRG1 promoter sequences –659 to –646, –644 to –636, –611 to –604, –590 to –582, and –612 to –592 each with an AvrII site (CCTAGG). The srg1-26 mutation contains three point mutations in the Cha4 consensus binding site within the SRG1 promoter (TGGAGATACATCTCCA to ctGAGATACATCTCaA). This mutant sequence has been shown to be defective for Cha4 binding (Holmberg and Schjerling 1996). The CHA4-Flag::kanMX allele encodes one copy of the Flag epitope at the 3′ end of CHA4, which was constructed by PCR-mediated integration using plasmid pDM714 (kind gift from D. Moazed, Harvard Medical School, Boston, MA). The gal1::SRG1p allele contains the SRG1 promoter and transcription initiation sites (base pairs –713 to –445 relative to the SER3 ATG) at position –556 of GAL1 (relative to GAL1 ATG). The gal1::srg1-1p allele has an insertion of the same DNA except with the srg1-1 promoter containing the TATA mutation. As indicated, strains were grown in either YPD (1% yeast extract, 2% peptone, and 2% glucose) or minimal media (0.145% yeast nitrogen base, 0.5% ammonium sulfate, 2% glucose, and supplemented with required amino acids) with 1 mM serine (SD + ser) or without serine (SD).
Northern analysis Northern hybridization analysis was performed as previously described (Ausubel et al. 1991). Probes for SER3, SRG1, and SNR190 were previously described (Martens and Winston 2002; Duina and Winston 2004; Martens et al. 2004). A probe specific to the GAL1 5′ UTR was generated by random labeling a PCR product, containing the GAL1 sequence from –443 to –157 (relative to the GAL1 ATG), amplified from genomic DNA. RNA levels were quantitated using a PhosphorImager (Molecular Dynamics) and normalized to SNR190, whose levels are unaffected by the mutations and growth conditions studied here. ChIP analysis ChIP analysis was performed as previously described (Dudley et al. 1999b; Martens and Winston 2002) with the following modifications: For the Cha4, Snf2, and Ada1 ChIPs, 200-mL cultures were grown to a density of 0.8 × 107 to 1.0 × 107 cells/mL in SD + ser medium and then split into two equal volumes. One half was treated with buffered formaldehyde (11% formaldehyde, 0.1M NaCl, 1 mM EDTA, and 50 mM Hepes-KOH at pH 7.5) to a final concentration of 1%. Cells from the other half of the culture were harvested by centrifugation, resuspended in SD medium, incubated for 25 min at 30°C, and then treated with buffered formaldehyde to a final concentration of 1%. The following antibodies were used for ChIP from one-fifth of the total amount of cross-linked chromatin: 4 μL of mouse A14 anti-myc ascites (Santa Cruz Biotechnology), 2 μL of rabbit anti-Flag M2 serum (Sigma-Aldrich, Inc), and 1 μL of rabbit anti-Ada1 serum (a generous gift from L. Guarente, Massachusetts Institute of Technology, Cambridge, MA). Input DNA (0.002% and 0.001%) and immunoprecipitated DNA (4% and 2% for Cha4-Flag and Snf2-myc, 2% and 1% for Ada1) were subjected to quantitative radioactive PCR and the products were separated on an 8% nondenaturing polyacrylamide gel. For the Gal4 ChIPs, 200-mL cultures were grown to a density of 1 × 107 to 2 × 107 cells/mL in YPD and then 37% formaldehyde was added to a final concentration of 1%. Gal4 was immunoprecipitated from one-tenth of the total amount of cross-linked chromatin with 1 μL; of anti-Gal4 serum (Santa Cruz Biotechnology, Inc.). Input DNA (0.002% and 0.001%) and immunoprecipitated DNA (1.33% and 0.67%) were analyzed as described for the Cha4 ChIPs. The PCR primers amplify the following regions whose coordinates are given relative to the SER3 ATG: SRG1 UAS primers amplify a 259-bp product from –714 to –456 and SER3 UAS primers amplify a 298-bp product from –234 to +65. Primers that amplify the GAL1 UAS and the control region from chromosome V that lacks open reading frames have been previously described (Dudley et al. 1999a; Komarnitsky et al. 2000). All ChIP experiments were quantitated by PhosphorImager analysis (Molecular Dynamics). Association of factors to specific DNA sequences was calculated as a percentage of the amount of coimmunoprecipitated DNA relative to the input DNA. Acknowledgments We thank Dominique Helmlinger and Natalie Kuldell for valuable comments on the manuscript and Amine Nourani and Randy Morse for helpful discussions. This work was supported by NIH grant GM32967 to F.W., by a postdoctoral fellowship from the Canadian Institute for Health Research to J.A.M, and by a predoctoral fellowship from the Howard Hughes Medical Institute to P.-Y.J.W. Notes Supplemental material is available at http://www.genesdev.org. Article and publication are at http://www.genesdev.org/cgi/doi/10.1101/gad.1367605. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||
Bioessays. 2003 Oct; 25(10):930-9.
[Bioessays. 2003]FEBS Lett. 2004 Jun 1; 567(1):27-34.
[FEBS Lett. 2004]Trends Genet. 2005 May; 21(5):289-97.
[Trends Genet. 2005]Trends Genet. 2005 Feb; 21(2):93-102.
[Trends Genet. 2005]Proc Natl Acad Sci U S A. 2002 Sep 17; 99(19):12257-62.
[Proc Natl Acad Sci U S A. 2002]Genes Dev. 2005 Jul 15; 19(14):1635-55.
[Genes Dev. 2005]Annu Rev Biochem. 2005; 74():199-217.
[Annu Rev Biochem. 2005]Annu Rev Microbiol. 2004; 58():303-28.
[Annu Rev Microbiol. 2004]Nature. 2004 Sep 16; 431(7006):343-9.
[Nature. 2004]FEBS Lett. 2004 Jun 1; 567(1):27-34.
[FEBS Lett. 2004]Genes Dev. 1987 May; 1(3):307-22.
[Genes Dev. 1987]Development. 1989 Oct; 107(2):321-9.
[Development. 1989]Proc Natl Acad Sci U S A. 1990 May; 87(9):3259-63.
[Proc Natl Acad Sci U S A. 1990]Development. 2002 Nov; 129(21):4923-30.
[Development. 2002]Nature. 2004 Jun 3; 429(6991):571-4.
[Nature. 2004]Genetics. 1996 Oct; 144(2):467-78.
[Genetics. 1996]Proc Natl Acad Sci U S A. 2003 Apr 1; 100(7):4084-9.
[Proc Natl Acad Sci U S A. 2003]Nature. 2004 Jun 3; 429(6991):571-4.
[Nature. 2004]Nature. 2004 Jun 3; 429(6991):571-4.
[Nature. 2004]Genetics. 1996 Oct; 144(2):467-78.
[Genetics. 1996]Proc Natl Acad Sci U S A. 2003 Apr 1; 100(7):4084-9.
[Proc Natl Acad Sci U S A. 2003]Proc Natl Acad Sci U S A. 2003 Apr 1; 100(7):4084-9.
[Proc Natl Acad Sci U S A. 2003]Cell. 1998 Nov 25; 95(5):717-28.
[Cell. 1998]Proc Natl Acad Sci U S A. 2000 Mar 28; 97(7):3364-9.
[Proc Natl Acad Sci U S A. 2000]Genes Dev. 2002 Sep 1; 16(17):2231-6.
[Genes Dev. 2002]Nature. 2004 Jun 3; 429(6991):571-4.
[Nature. 2004]Genes Dev. 1997 Jul 1; 11(13):1640-50.
[Genes Dev. 1997]Nature. 2004 Jun 3; 429(6991):571-4.
[Nature. 2004]Proc Natl Acad Sci U S A. 2003 Apr 1; 100(7):4084-9.
[Proc Natl Acad Sci U S A. 2003]Nature. 2004 Jun 3; 429(6991):571-4.
[Nature. 2004]Genetics. 1996 Oct; 144(2):467-78.
[Genetics. 1996]Proc Natl Acad Sci U S A. 2003 Apr 1; 100(7):4084-9.
[Proc Natl Acad Sci U S A. 2003]Science. 2003 Jul 4; 301(5629):71-6.
[Science. 2003]Nature. 2003 May 15; 423(6937):241-54.
[Nature. 2003]Nature. 2004 Jun 3; 429(6991):571-4.
[Nature. 2004]Proc Natl Acad Sci U S A. 2003 Apr 1; 100(7):4084-9.
[Proc Natl Acad Sci U S A. 2003]Mol Cell Biol. 2004 Jan; 24(2):561-72.
[Mol Cell Biol. 2004]Trends Biochem Sci. 2005 Jul; 30(7):405-12.
[Trends Biochem Sci. 2005]Proc Natl Acad Sci U S A. 2003 Apr 1; 100(7):4084-9.
[Proc Natl Acad Sci U S A. 2003]Mol Cell Biol. 1991 Jan; 11(1):564-7.
[Mol Cell Biol. 1991]EMBO J. 2003 Oct 1; 22(19):5147-53.
[EMBO J. 2003]Trends Genet. 2005 Jun; 21(6):339-45.
[Trends Genet. 2005]J Mol Biol. 1979 Jan 25; 127(3):353-6.
[J Mol Biol. 1979]Nature. 1984 Jan 19-25; 307(5948):241-5.
[Nature. 1984]Nature. 1986 Aug 7-13; 322(6079):562-5.
[Nature. 1986]Nature. 1989 Jan 19; 337(6204):279-82.
[Nature. 1989]Mol Cell. 2000 Feb; 5(2):377-86.
[Mol Cell. 2000]Genes Dev. 2005 Mar 15; 19(6):697-708.
[Genes Dev. 2005]Bioessays. 2003 Oct; 25(10):930-9.
[Bioessays. 2003]FEBS Lett. 2004 Jun 1; 567(1):27-34.
[FEBS Lett. 2004]Trends Genet. 2005 May; 21(5):289-97.
[Trends Genet. 2005]Yeast. 1995 Jan; 11(1):53-5.
[Yeast. 1995]Genetics. 1994 Jul; 137(3):647-57.
[Genetics. 1994]Nucleic Acids Res. 1986 Sep 11; 14(17):6885-900.
[Nucleic Acids Res. 1986]Genetics. 1992 Oct; 132(2):361-74.
[Genetics. 1992]Genetics. 1995 Feb; 139(2):523-36.
[Genetics. 1995]Genes Dev. 2002 Sep 1; 16(17):2231-6.
[Genes Dev. 2002]Mol Cell Biol. 2004 Jan; 24(2):561-72.
[Mol Cell Biol. 2004]Nature. 2004 Jun 3; 429(6991):571-4.
[Nature. 2004]Genes Dev. 1999 Nov 15; 13(22):2940-5.
[Genes Dev. 1999]Genes Dev. 2002 Sep 1; 16(17):2231-6.
[Genes Dev. 2002]Genetics. 1999 Apr; 151(4):1365-78.
[Genetics. 1999]Genes Dev. 2000 Oct 1; 14(19):2452-60.
[Genes Dev. 2000]Genes Dev. 2000 Oct 1; 14(19):2452-60.
[Genes Dev. 2000]Genes Dev. 1999 Nov 15; 13(22):2940-5.
[Genes Dev. 1999]Science. 2000 Dec 22; 290(5500):2306-9.
[Science. 2000]Nature. 2004 Jun 3; 429(6991):571-4.
[Nature. 2004]